Two Sigma Investments, LP Genfit S.A. Transaction History

Two Sigma Investments, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.54 - $4.68 $24,780 - $32,759	-7,000 Reduced 32.76%	14,365 $50,000
Q1 2023 May 15, 2023	SELL	$3.93 - $4.69 $56,336 - $67,231	-14,335 Reduced 40.15%	21,365 $87,000
Q4 2022 Feb 14, 2023	SELL	$3.53 - $4.39 $102,475 - $127,441	-29,030 Reduced 44.85%	35,700 $156,000
Q3 2022 Nov 14, 2022	SELL	$3.26 - $4.86 $50,986 - $76,010	-15,640 Reduced 19.46%	64,730 $236,000
Q2 2022 Aug 15, 2022	SELL	$3.09 - $4.25 $74,947 - $103,083	-24,255 Reduced 23.18%	80,370 $259,000
Q1 2022 May 16, 2022	BUY	$3.14 - $5.04 $57,314 - $91,995	18,253 Added 21.13%	104,625 $419,000
Q4 2021 Feb 14, 2022	BUY	$3.01 - $5.65 $259,979 - $488,001	86,372 New	86,372 $432,000

49.2K

Ticker GNFT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,815,500
Market Cap $274M
Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.